Novo Nordisk
The pharma giant will deploy OpenAI's most advanced capabilities across its global operations, from drug discovery to commercial functions, and upskill its workforce in AI literacy.
The pharma giant alleges that Hims & Hers is infringing its patents and misleading consumers by selling unsafe, unapproved compounded versions of its semaglutide drugs.
The collaboration will allow patients considering the oral GLP-1 therapy to access metabolic care through knownwell’s hybrid model.
TrumpRx will offer Novo Nordisk's Ozempic and Wegovy for $350 and Eli Lilly and Company's Zepbound and orforglipron, if approved by the FDA, for $346.
Ozempic and Wegovy pens will be available via GoodRx for $499 per month.
The announcement comes the same week the pharma giant ended its collaboration with Hims & Hers to sell Wegovy, alleging the company engages in deceptive marketing and illegally sells copycat drugs.
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.
Americans with a prescription will have access to Novo Nordisk's obesity drug Wegovy through the Hims & Hers platform for $599 monthly.
Novo Nordisk is bringing its expertise in chronic disease management to Kakao's mobile diabetes app.
The partnership includes a patient support programme that brings tailored and age-based educational content to patients with Type 1 diabetes.